Clopidogrel Tablet
Product Images NDC 71335-0581

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 71335-0581). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-03 (Clopidogrel Fig 3)

A forest plot chart depicting hazard ratios with 95% confidence intervals for subgroups comparing Clopidogrel and placebo. Subgroups include Heparin/LMWH use, Aspirin dosage, GPIIb/IIIa antagonist use, Beta-Blocker use, and ACE Inhibitor use. The plot shows point estimates and confidence intervals favoring Clopidogrel or placebo for each subgroup and overall comparison.*

FDA Label Image

Figure-1 (Clopidogrel Figure 01)

A horizontal bar chart illustrating the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite AUC of Clopidogrel. The chart compares Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, showing mean values with 90% confidence intervals indicating changes relative to Clopidogrel administered alone.*

FDA Label Image

Figure-2 (Clopidogrel Figure 02)

A line graph showing cumulative event rates of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. It compares two groups: one treated with placebo plus aspirin and the other with clopidogrel plus aspirin, with the clopidogrel group showing a consistently lower event rate. A p-value of 0.00009 is indicated, suggesting statistical significance.*

FDA Label Image

Figure-4 (Clopidogrel Figure 04)

A line graph comparing percent dead before first discharge over 28 days between placebo and Clopidogrel groups. The graph shows a 7% proportional risk reduction in death for the Clopidogrel group (7.5% deaths) versus placebo (8.1% deaths). The x-axis represents days since randomization, and the y-axis shows the percent dead before first discharge.*

FDA Label Image

Figure-5 (Clopidogrel Figure 05)

A line graph showing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days since randomization. Two curves compare placebo and Clopidogrel-treated groups, with the placebo group showing a higher percentage of events than the Clopidogrel group.*

FDA Label Image

Fig-7 (Clopidogrel Figure 07)

A line graph showing cumulative event rates (%) of fatal or non-fatal vascular events over months of follow-up, comparing aspirin and clopidogrel. The vertical axis represents cumulative event rate percentages up to 16%, and the horizontal axis displays months from 0 to 36. The graph includes a p-value of 0.045.*

FDA Label Image

Figure-3 (Clopidogrel Figure 3)

A forest plot chart comparing the effects of Clopidogrel versus placebo across various subgroups including age, gender, race, elevated cardiac enzymes, diabetes status, previous myocardial infarction, and previous stroke. The chart presents hazard ratios with 95% confidence intervals, showing the direction and magnitude of effect for Clopidogrel relative to placebo.*

FDA Label Image

Figure-6 (Clopidogrel Figure 6)

A forest plot chart illustrating the odds ratios with 99% confidence intervals comparing Clopidogrel and placebo across various subgroups including gender, age ranges, hours since onset, systolic blood pressure (SBP) ranges, heart rate categories, and fibrinolytic agent use. The plot visually indicates favorability towards Clopidogrel or placebo along a horizontal axis.*

FDA Label Image

Figure-8 (Clopidogrel Figure 8)

A forest plot chart showing hazard ratios with 95% confidence intervals for Clopidogrel versus Aspirin across qualifying conditions: Stroke, MI, PAD, and Overall. The x-axis represents the hazard ratio scale from 0.6 to 1.3, indicating the comparative favors between Clopidogrel and Aspirin.*

FDA Label Image

Structure (Clopidogrel Structure)

Chemical structure of Clopidogrel as shown in the image, including its molecular components and arrangement, with a note of associated sulfuric acid (H2SO4).*

FDA Label Image

Label Image (Lbl713350581)

Clopidogrel 75 mg Tablet packaging label by Bryant Ranch Prepack, featuring a pink round tablet imprint L11. The label notes comparison to Plavix 75 mg Tablet by Macleods Pharmaceuticals Ltd. It includes storage instructions at 20°-25°C (68°-77°F), a barcode, and an NDC 71335-0581 for a 90-count package.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.